Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer
Authors:
- 25 October 2008
- journal article
- research article
- Published by Wiley in World Journal of Surgery
- Vol. 33 (1) , 44-51
Abstract
Background: Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early‐stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment.Methods: From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment.Results: The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous‐type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis.Conclusions: In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane.Keywords
This publication has 22 references indexed in Scilit:
- HER2 and Response to Paclitaxel in Node-Positive Breast CancerNew England Journal of Medicine, 2007
- Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: Results of a phase II studyEuropean Journal of Cancer, 2006
- Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institutionAnnals of Oncology, 2006
- Treatment Options in Metastatic Renal Carcinoma: An Embarrassment of RichesJournal of Clinical Oncology, 2006
- Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiationJournal of Clinical Pathology, 2005
- High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancerBreast Cancer Research and Treatment, 2005
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerJournal of Clinical Oncology, 2005
- The Use of Contrast-Enhanced Computed Tomography Before Neoadjuvant Chemotherapy to Identify Patients Likely to Be Treated Safely With Breast-Conserving SurgeryAnnals of Surgery, 2004
- Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancerEuropean Journal of Cancer, 2003
- Breast conservative surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy. A pathological assessmentThe Breast, 1999